These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27514759)

  • 21. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes.
    Dubuquoy C; Robichon C; Lasnier F; Langlois C; Dugail I; Foufelle F; Girard J; Burnol AF; Postic C; Moldes M
    J Hepatol; 2011 Jul; 55(1):145-53. PubMed ID: 21145868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.
    Palmer CN; Maglio C; Pirazzi C; Burza MA; Adiels M; Burch L; Donnelly LA; Colhoun H; Doney AS; Dillon JF; Pearson ER; McCarthy M; Hattersley AT; Frayling T; Morris AD; Peltonen M; Svensson PA; Jacobson P; Borén J; Sjöström L; Carlsson LM; Romeo S
    PLoS One; 2012; 7(6):e39362. PubMed ID: 22724004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
    Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
    Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
    Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
    J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.
    Qadri S; Lallukka-Brück S; Luukkonen PK; Zhou Y; Gastaldelli A; Orho-Melander M; Sammalkorpi H; Juuti A; Penttilä AK; Perttilä J; Hakkarainen A; Lehtimäki TE; Orešič M; Hyötyläinen T; Hodson L; Olkkonen VM; Yki-Järvinen H
    Liver Int; 2020 Sep; 40(9):2128-2138. PubMed ID: 32386450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.
    Kotronen A; Johansson LE; Johansson LM; Roos C; Westerbacka J; Hamsten A; Bergholm R; Arkkila P; Arola J; Kiviluoto T; Fisher RM; Ehrenborg E; Orho-Melander M; Ridderstråle M; Groop L; Yki-Järvinen H
    Diabetologia; 2009 Jun; 52(6):1056-60. PubMed ID: 19224197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.
    Luukkonen PK; Qadri S; Lehtimäki TE; Juuti A; Sammalkorpi H; Penttilä AK; Hakkarainen A; Orho-Melander M; Arola J; Yki-Järvinen H
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e300-e315. PubMed ID: 33064150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.
    Santoro N; Kursawe R; D'Adamo E; Dykas DJ; Zhang CK; Bale AE; Calí AM; Narayan D; Shaw MM; Pierpont B; Savoye M; Lartaud D; Eldrich S; Cushman SW; Zhao H; Shulman GI; Caprio S
    Hepatology; 2010 Oct; 52(4):1281-90. PubMed ID: 20803499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity.
    Moschen AR; Wieser V; Gerner RR; Bichler A; Enrich B; Moser P; Ebenbichler CF; Kaser S; Tilg H
    J Hepatol; 2013 Dec; 59(6):1315-22. PubMed ID: 23928404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice.
    Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Ronda OAHO; Verkade HJ; Stojakovic T; Scharnagl H; Trauner M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status.
    Hoekstra M; Li Z; Kruijt JK; Van Eck M; Van Berkel TJ; Kuiper J
    J Hepatol; 2010 Feb; 52(2):244-51. PubMed ID: 20015565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease.
    Delik A; Akkız H; Dinçer S
    Indian J Gastroenterol; 2020 Feb; 39(1):84-91. PubMed ID: 32333362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
    Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings.
    Mantovani A; Taliento A; Zusi C; Baselli G; Prati D; Granata S; Zaza G; Colecchia A; Maffeis C; Byrne CD; Valenti L; Targher G
    Liver Int; 2020 May; 40(5):1130-1141. PubMed ID: 32125756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.